Digital Pathogy for Biomarkers, Andrew Vickers, Decision Theory

 Digital Pathology can potentially be a useful test to triage cases that get e.g. MSI testing or not.  (But note recent papers on whether digital pathology prediction of biomarkers may suffer confounding which affects apparent accuracy).

See a Linked In blog on the topic of dig path screening prior to genomics, by Katherina von Loga at WAIV former OWKIN DX.

https://www.linkedin.com/posts/kvonloga_the-other-side-of-the-coin-in-precision-medicine-share-7442546485084385281-xT3-/

###

Andrew Vickers at MSKCC has done great work on the statistics of this decision theory problem.

For example, he models insertion of kallikrein biomarkers to REDUCE the number of physical prostate biopsies.   This probably models similarly to using Dig Path to REDUCE the number of physical MSI genomics.

###

Yes — the person is Andrew J. Vickers, PhD, of Memorial Sloan Kettering. He is an attending research methodologist/biostatistician at MSK, with a particular focus on prostate cancer detection, prediction models, and decision-making. MSK’s own profile highlights his work on baseline PSA, PSA velocity, MRI targeting, Gleason grading, and active surveillance, which fits your recollection very well. (Memorial Sloan Kettering Cancer Center)

The core methodological idea he is most associated with is decision curve analysis (DCA). In his 2006 paper, Vickers argued that the right question is not merely whether a model has a better ROC curve or AUC, but whether using it in practice would actually do more good than harm. DCA does this by calculating net benefit across a range of threshold probabilities — in other words, across the range of risk levels at which a clinician or patient would reasonably choose biopsy or treatment. That is exactly the framework for judging an intermediate test that sits between a screening marker and a definitive but invasive procedure. (PubMed)

In prostate cancer, this became especially important because a test like PSA or a multivariable marker panel is not the end point; the practical question is whether it improves the decision to proceed to needle biopsy. Vickers and colleagues showed that a four-kallikrein panel could predict biopsy outcome in men with elevated PSA and that its use could substantially reduce unnecessary biopsies, with most missed cancers tending to be lower-stage, lower-grade disease rather than the clinically most dangerous tumors. (PubMed)

That body of work is closely linked to what became the 4Kscore. A later European Urology paper explicitly described the four-kallikrein statistical model as commercially available as the 4Kscore and examined its value across biopsy subgroups, again squarely in the setting of deciding when an elevated PSA should lead to biopsy. (PubMed)

So, in practical terms, Vickers’ contribution was to formalize a clinically realistic way to ask: Does this intermediate test improve the biopsy decision enough to justify using it? Not “is it statistically associated with cancer,” but “does it improve decisions, reduce unnecessary procedures, and preserve detection of important disease?” That is why his work has been so influential far beyond prostate cancer. The 2006 DCA paper has been cited extensively, and his later tutorial paper was written precisely because the method became widely used across medicine. (PubMed)

If helpful, I can next give you a one-paragraph explanation of decision curve analysis in plain English, or a short list of the 3–5 classic Vickers papers on this topic.

###

Plain-English one-paragraph explanation:
Decision curve analysis asks a practical question: not merely whether a test is statistically associated with cancer, but whether using it would lead to better decisions for real patients. In the prostate setting, that means asking whether an intermediate test such as PSA or a four-kallikrein panel/4Kscore helps decide who should go on to biopsy in a way that produces more benefit than harm. Vickers’ framework does this by calculating net benefit across a range of clinically reasonable risk thresholds—the point at which a patient or doctor would say, “Yes, this risk is high enough that biopsy is worth it.” That made it possible to judge intermediate tests by their clinical utility—how many unnecessary biopsies they avoid while still preserving detection of important cancers—rather than by AUC alone. (PubMed)

Here are 5 core Andrew Vickers papers on this theme, with PMIDs and brief summaries:

1) Vickers AJ, Elkin EB. “Decision curve analysis: a novel method for evaluating prediction models.” Med Decis Making. 2006. PMID: 17099194.
This is the foundational paper. It introduces decision curve analysis and the concept of net benefit, showing how to evaluate models in terms of whether they improve decisions, not just whether they improve statistical fit or discrimination. This is the key methods paper behind later work on PSA, kallikreins, and biopsy decision-making. (PubMed)

2) Vickers AJ, Cronin AM, Elkin EB, Gonen M. “Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers.” BMC Med Inform Decis Mak. 2008. PMID: 19036144.
This is the important follow-on methods paper. It expands the original DCA framework and shows how it can be used more broadly for diagnostic tests, prediction models, and molecular markers—very much the category into which intermediate screening tests fall. If the 2006 paper gave the concept, this paper made it easier to use in real biomarker research. (PubMed)

3) Vickers AJ, Cronin AM, Aus G, et al. “A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands.” Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18611265.
This is one of the classic early kallikrein papers. It showed that combining multiple kallikrein forms in blood could improve prediction of biopsy outcome in men with elevated PSA, and that a multivariable model could help determine which men should proceed to biopsy and which could reasonably defer biopsy and continue screening. In other words, it made the intermediate-test idea operational. (PubMed)

4) Vickers AJ, Cronin AM, Roobol MJ, et al. “Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.” J Clin Oncol. 2010. PMID: 20421547.
This is a major replication/validation paper and one of the most directly relevant to your recollection. It reported that the four-kallikrein panel could predict biopsy outcome in men with elevated PSA and that using it would dramatically reduce biopsy rates. The tradeoff was that some cancers would be missed initially, but those missed cases were said to be predominantly low-stage, low-grade disease, supporting the clinical value of the test as an intermediate triage step. (PubMed)

5) Vickers AJ, Cronin AM, Aus G, et al. “A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.” Cancer Prev Res (Phila). 2010. PMID: 20400522.
This paper focused on previously screened men, an especially important population because biopsy decisions become trickier after prior PSA testing. It found that the statistical model based on the four-kallikrein panel could substantially decrease unnecessary biopsy in this setting as well. Together with the other 2010 paper, it helped establish the practical case for what later became the 4Kscore-type approach. (PubMed)

A useful later teaching paper, though not prostate-specific, is Vickers AJ, van Calster B, Steyerberg EW. “A simple, step-by-step guide to interpreting decision curve analysis.” Diagn Progn Res. 2019. PMID: 31592444. It is probably the best short “how to read a DCA graph” explainer. (PubMed)

If you want, I can next turn these into a mini reading guide in your usual memo style: “start here, then read these two prostate papers, then the tutorial.”

Notes on RVU Resources

 

AMA DETAILED RESOURCES

AMA (2025a) Practice Expense Component. (COGS & CMS RVU) (27p PDF). Available at: https://www.ama-assn.org/system/files/practice-expense-component.pdf.

Above PDF found at AMA 2025b.

 

AMA (2025b) RVRVS Overview (home page). Available at: https://www.ama-assn.org/about/rvs-update-committee-ruc/rbrvs-overview.

 

ARCHIVAL VIEWS OF RVUs

Hsiao, W.C. et al. (1988) “Resource-based relative values. An overview,” JAMA, 260(16), pp. 2347–2353.

Roe, B.B. (1981) “Sounding boards. The UCR boondoggle: a death knell for private practice?,” The New England Journal of Medicine, 305(1), pp. 41–45. Available at: https://doi.org/10.1056/NEJM198107023050108.

MODERN EXPLANATIONS OF RVU PROCESSES (SEE ALSO "AMA")

 

Jacobs, J.P. et al. (2017) “How Is Physician Work Valued?,” The Annals of Thoracic Surgery, 103(2), pp. 373–380. Available at: https://doi.org/10.1016/j.athoracsur.2016.11.059.

 

McMahon, L.F. and Song, Z. (2024) “Rebuilding the Relative Value Unit-Based Physician Payment System,” JAMA, 332(5), pp. 369–370. Available at: https://doi.org/10.1001/jama.2024.8478.

 

 

LAB SPECIFIC - ONLY WEISS = PATHOLOGY

Sireci, A.N. et al. (2020) “Molecular Pathology Economics 101: An Overview of Molecular Diagnostics Coding, Coverage, and Reimbursement: A Report of the Association for Molecular Pathology,” The Journal of molecular diagnostics: JMD, 22(8), pp. 975–993. Available at: https://doi.org/10.1016/j.jmoldx.2020.05.008.

 

Weiss, R.L. (2007) “Coding, coverage, and compensation for pathology and laboratory medicine services,” Clinics in Laboratory Medicine, 27(4), pp. 875–891, viii. Available at: https://doi.org/10.1016/j.cll.2007.07.004

QUINN

Quinn, B. (2026a) “AI History You Can Use: Pricing Novel Technologies in RVUs - Case Studies 2010, 2020,” BruceBlogMiscellaneous. Available at: https://bqwebpage.blogspot.com/2026/03/ai-history-you-can-use-pricing-novel.html.

Quinn, B. (2026b) “Notes on RVU Resources,” BruceBlogMiscellaneous. Available at: https://bqwebpage.blogspot.com/2026/03/notes-on-rvu-resources.html.

Michael J Fox Foundation - Parkinson's and Sleep Panel (March 2026)

The Michael J Fox Parkinson Foundation has a monthly webinar on related topics.  For March, the topic was Parkinson's and sleep.   

I was curious how Chat GPT might summarize it - the result, below.

###

https://www.michaeljfox.org/webinars

https://www.michaeljfox.org/webinar/sleep-and-parkinsons-whats-going-and-what-can-help

Soania Mathur MD / MJFF Patient Council

Wanda Kim Lilly / Patient / MJFF Patient Council

Emmanuel During MD / Icahn School of Medicine / Mt Sinai / NYC

Lkeanis Vaou MD, FAAN, Univ Texas San Antonio

###

AI PARODY: Cenozoic Park

 

CENOZOIC PARK
A Whimsical Counterfactual Treatment

---

Logline

A visionary biotech magnate resurrects an island full of adorably small Paleogene mammals, only to insist on building fortress-grade containment for creatures that look like plush toys. Visiting scientists begin to wonder: is he mad—or is “cute” the most dangerous evolutionary strategy of all?

---

Act I – Welcome to the Age of Mammals

A helicopter sweeps over a misty island off the Pacific coast. Instead of thunderous roars, we hear… soft chirps, rustles, and faint squeaks.

Enter Dr. Basil Thorne, founder of CenoGenesis, a man with the eyes of a prophet and the posture of someone who has not slept since the Eocene. He unveils CENOZOIC PARK, a revolutionary theme park populated not by dinosaurs—but by resurrected early mammals:

• Tiny, fox-like Miacids dart through brush

• Lemur-like plesiadapiforms cling to branches

• Beaver-sized Castoroides pups paddle in lagoons

• Shrew-elephant hybrids blink with implausible sweetness

The investors are charmed. The children are enchanted. The merchandising rights alone could fund a small nation.

But the visiting scientists—our ensemble of skeptics—notice something… off.

Every enclosure is absurdly overbuilt:

• 30-foot steel walls

• Triple-layer electric fencing

• Barbed wire coiled like a Cold War border

Inside: a creature the size of a guinea pig, blinking.

“Dr. Thorne,” one scientist ventures, “what exactly are we containing?”

Thorne smiles, beatifically.
“Potential.”

---

Act II – The Problem with Cute

The scientists begin their tour.

At first, everything is delightful:

• A swarm of velvety multituberculates gather like living slippers

• A family of early primates curiously examine visitors’ glasses

• A burrow erupts in synchronized squeaks, like a wind-up toy orchestra

But then:

• A caretaker reports that a fenced enclosure appears empty—until a thermal camera reveals hundreds of creatures pressed silently against the wall

• A biologist notices that feeding stations are being systematically dismantled—from the inside

• A small mammal demonstrates an unsettling ability to coordinate movement in groups, like schooling fish

Still, they’re… cute.

Thorne grows increasingly animated.
“You’re thinking like Mesozoic men,” he lectures. “Teeth, claws, spectacle! But mammals—mammals win by adaptability.”

Then the power flickers.

---

Act III – Containment Failure (Soft Edition)

The storm hits. Lightning cracks. The fences go dark.

There is no roar.
No thunder of footsteps.

Instead:

A silence.

Then—movement.

Tiny shapes pour through the underbrush. Not attacking. Not fleeing. Organizing.

The scientists scramble to regroup as:

• Swarms of small mammals short-circuit control panels by sheer accumulation

• A pack of fox-sized predators executes a coordinated diversion, drawing guards away

• Hundreds of creatures quietly occupy buildings, learning layouts, opening latches, observing

It’s not chaos.

It’s strategy.

One scientist whispers, stunned:
“They’re not escaping… they’re taking inventory.”

---

Denouement – The Unnerving Revelation

At dawn, the storm clears.

The park is… calm.

No bodies. No blood. No dramatic carnage.

Instead:

• The animals have retreated to enclosures voluntarily

• Systems are partially restored—but subtly altered

• Doors open when approached. Lights flicker in patterns

The scientists prepare to evacuate, shaken but unharmed.

Dr. Thorne stands at the overlook, serene.

“You see?” he says softly. “No monsters. No spectacle. Just… intelligence finding its level.”

A final shot:

A small, soft-eyed mammal sits at a control console,
tiny paws resting on a keyboard.

It tilts its head.
Presses a key.

The perimeter fences power back on.

From the inside.

---

Closing Note (Tone)

Cenozoic Park replaces terror with something more disquieting: the idea that the most successful creatures in Earth’s history were not the largest or the fiercest—but the most adaptable, social, and quietly observant.

Also, they’re extremely marketable as plush toys.

AI Parody: Guess Who's Coming to Dinner

 

Guess Who’s Coming to Dinner, Joanna
A Review

There are films whose premises are so flagrantly idiotic that criticism, if it is to survive with any dignity, must proceed by a kind of tactical surrender. One cannot quite “evaluate” such a work in the ordinary way; one can only describe the strange social and artistic weather system it creates and then report from inside it, like a correspondent embedded with a particularly well-dressed nervous breakdown. Guess Who’s Coming to Dinner, Joanna, the new counterfactual reimagining of Stanley Kramer’s 1967 liberal monument, belongs emphatically to this category. Its central device—that the Sidney Poitier figure, Dr. John Prentice, arrives not with Joanna Drayton but with an inflatable sex doll whom he identifies, without irony or hesitation, as Joanna—is so manifestly preposterous that one expects the film to collapse at once into skit. What is remarkable is that it does not. Or rather, it does collapse, but with such stateliness, such ceremonious self-command, that the collapse itself becomes the subject.

The film’s great inspiration is to understand that the true comic material lies not in the doll, which is after all only an object, but in the bourgeois commitment to behaving as though objects can be reasoned with so long as they are introduced politely. In the original Guess Who’s Coming to Dinner, liberal America is confronted with a moral challenge it congratulates itself for ultimately surviving. In this version, liberal America is confronted with something worse: an event for which it possesses no approved vocabulary. It knows how to discuss race, justice, equality, and generational change. It does not know how to discuss a vinyl blonde in a summer dress seated on the divan with the solemnity of a future daughter-in-law. The result is a comedy of moral unpreparedness. The Draytons, who in another film might rise nobly to history, are here reduced to the much narrower and more agonizing question of whether one is obliged to offer canapés to an inflatable guest.

Much of the film’s brilliance lies in its refusal of exaggeration. John Prentice is not played as a lunatic. He is played, fatally, as a man of almost supernatural poise. This is what gives the film its unnerving ballast. Had he arrived ranting or disheveled, the narrative would have some practical place to go. But because he is grave, intelligent, elegantly spoken, and entirely sincere in his treatment of “Joanna,” everyone else is trapped within the etiquette of uncertainty. The film grasps a truth that far exceeds satire: among educated people, madness is most powerful when impeccably mannered. An incoherent man can be removed; a coherent man accompanied by nonsense must be listened to.

The house itself, with its polished surfaces and mid-century confidence, becomes a kind of laboratory for testing the tensile strength of civility. Every room seems designed for adult conversation of a tasteful kind, and the film’s most persistent joke is that each of these rooms proves wholly inadequate to the emergency it contains. One begins to see how much of upper-class domestic life depends on the assumption that no truly disreputable absurdity will ever enter it through the front door. Once it does, the machinery of hospitality—cocktails, seating, tact, lowered voices—goes on operating long after it has ceased to be useful. Christina Drayton’s attempts to make the doll comfortable are among the film’s finest inventions, not because they are flamboyantly funny, but because they are exactly what a certain kind of well-brought-up woman would do when deprived of any socially legible action. If reality cannot be mastered, perhaps it can at least be fluffed.

What the film parodies, then, is not merely one movie but an entire moral style: the American belief that difficult truths are best handled in drawing rooms by articulate people who remain seated. Here the drawing room remains, and the articulacy remains, but truth itself has become vulgar, elusive, and faintly rubberized. Time and again the characters try to elevate the situation into something discussable—psychological trauma, symbolic substitution, modern estrangement, perhaps even a critique of domestic femininity—because the plain facts are too humiliatingly plain. Their error is the classic error of cultivated intelligence: they mistake interpretation for courage. The more they explain, the less they understand. The film might be described, in this respect, as Buñuel by way of Berkeley.

The arrival of John’s parents deepens the satire beautifully. What in the original was a doubling of moral gravity becomes here a doubling of interpretive panic. More respectable adults enter the frame, and so more language is deployed against the unbearable sight at its center. A family drama becomes, by increments, a symposium on denial. The speeches accumulate. Feeling swells. One waits for wisdom and gets only vocabulary. This is not a defect of the film but its point: the rhetoric of seriousness is shown to be one of the principal ways serious people protect themselves from the immediate claims of the real. The doll, mute and smiling, defeats them all.

The eventual appearance of the real Joanna is wisely delayed until the film has nearly exhausted the interpretive resources of its characters. When she arrives, carrying a bag and an expression of dry human irritation, she restores not merely plot but ontology. Her indignation is directed less at John’s grotesque substitution than at the fact that everyone has been politely collaborating with it. This is the film’s hardest and best joke. Absurdity, left alone, is only absurdity; absurdity treated with ceremony becomes culture. Joanna’s speech cuts through the house like fresh air through a stale salon. She names what the others have merely circled. In doing so, she reveals that the opposite of repression is not passion but accuracy.

One should not overstate the film’s ambitions, although the film itself encourages one to do precisely that. Its deeper satirical target is male composure—the educated, accomplished, morally handsome form of composure that can withstand anything except contradiction. John Prentice’s substitution of a doll for a woman who has left him is ridiculous, yes, but it is also a distilled caricature of a more familiar fantasy: the wish that love might remain in place so long as its outward forms are preserved. The dinner will proceed, the family will convene, approval will be sought, and reality, if necessary, can be upholstered. It is an exquisitely masculine delusion, and the film is shrewd enough to let it appear not monstrous at first, but merely composed.

The ending, in which Matt Drayton rises for what seems the obligatory concluding speech and instead confesses bafflement, is nearly perfect. It is the only truly moral gesture in the picture, because it abandons the vanity of moral performance. By then, the housekeeper—who has understood the entire situation from the start with the invincible clarity of those not overinvested in appearing profound—removes the doll under one arm like a decorative object whose season has passed. Few recent images have so elegantly summarized the fate of cultivated nonsense.

One leaves Guess Who’s Coming to Dinner, Joanna with the odd sensation of having watched both a parody and a diagnosis. It is, obviously, very funny. But its funniness depends on a painful recognition: civilized people are often most ridiculous at the precise moment they believe themselves most enlarged by tolerance. The film’s achievement is to turn this recognition into form. It asks what happens when a society trained to discuss every moral difficulty with fluent seriousness is confronted not with evil, or even prejudice, but with something that is merely appalling and idiotic. The answer, it turns out, is dinner.

AI Book Review: Erin McGoff, The Secret Language of Work

 

Erin McGoff’s book—built out of the sensibility that made her YouTube and TikTok presence so popular—lands in a space that is surprisingly underdeveloped in traditional career literature: the translation of “professional success” into actual words, sentences, and scripts that real people can use in real moments. What she calls the “secret language of work” is essentially a modern reframing of what sociologists would call the hidden curriculum: the unwritten rules that determine who advances and who stalls.

What distinguishes this book from the crowded field of career advice is its granularity and operational tone. McGoff does not merely advise readers to “be confident” or “advocate for yourself.” Instead, she provides verbatim phrasing, structured scenarios, and even tactical linguistic devices—like the “no-facing question” in salary negotiations—that transform abstract advice into something executable. This is where her background as a digital creator shows: the material reads like a well-edited series of scripts refined through audience feedback rather than a top-down theory of management.

At its core, the book is about communication as leverage. Whether negotiating salary, asking for a raise, networking, or setting boundaries with a boss, McGoff consistently reframes workplace interactions as transactional but human exchanges, where clarity, tone, and timing matter as much as content. Her advice on compensation discussions, for example, strips away emotional hesitation and replaces it with a business-case mindset—an approach that is both practical and psychologically liberating for early-career readers.

One of the strongest sections addresses networking, an area often treated with either cynicism or vagueness in other books. McGoff breaks it into warm and cold outreach, offering highly specific templates and emphasizing reciprocity and value creation. The insistence on brevity, personalization, and genuine engagement reflects not just etiquette but an understanding of modern attention economics. Her analogy of networking as a form of “hacky sack”—a back-and-forth exchange—captures the rhythm of good conversation in a way that is memorable and actionable.

Equally compelling is her treatment of the first 90 days in a job, where she emphasizes expectation-setting as a strategic act. The principle of “under promise and over deliver” is hardly new, but her illustration of how identical work can be perceived as either disappointing or impressive depending on framing is particularly effective. This reflects a broader theme of the book: performance is not just what you do, but how others interpret what you do.

McGoff also deserves credit for foregrounding social inequality without turning the book into a manifesto. The opening contrast between Samantha and Jessie—two equally capable candidates with different exposure to professional norms—quietly but powerfully illustrates how access to the hidden curriculum shapes outcomes. The book’s mission, then, is not merely to offer tips, but to democratize access to these unwritten rules.

Stylistically, the book is energetic, conversational, and occasionally irreverent, with a tone that will resonate strongly with younger readers. Lines like “you have to be the hero of your own story” and the playful caution against being “Elizabeth Holmes–level delusional” give the text a contemporary voice without undermining its seriousness. At times, this tone may feel slightly over-bright to a more seasoned reader, but it is clearly calibrated to her audience.

If there is a limitation, it lies in the book’s intentional narrowness. It is not a deep dive into organizational behavior, labor economics, or long-term career strategy. Instead, it focuses tightly on micro-interactions—emails, conversations, negotiations. For its target audience, this is a strength; for more senior professionals, it may feel like a toolkit rather than a philosophy.

In sum, Erin McGoff has produced a book that is highly practical, psychologically astute, and unusually usable. It translates the often opaque norms of professional life into a set of learnable skills, delivered with clarity and momentum. For readers early in their careers—or anyone who has ever thought, “I know what I want, but I don’t know how to say it”—this book will feel less like advice and more like access.

DOJ and Oncotype 2023 Settlement (No Admission)

 In 2023, Genomic Health settled with DOJ for $32M re 14 day rule activities.  No admission of wrongdoing was made.

Here are some links including the 18 page settlement.  Then, I give an AI summary.

DOJ Press

https://www.justice.gov/archives/opa/pr/genomic-health-inc-agrees-pay-325-million-resolve-allegations-relating-submission-false

Phillips Cohen

https://www.phillipsandcohen.com/genomic-health-pays-32-5m-to-settle-medicare/

Tycko

https://www.fraudfighters.net/news/whistleblowers-5-6-million-genetic-testing-medicare-billing-fraud/

Wolters

https://www.vitallaw.com/news/false-claims-act-settlement-agreements-genomic-health-to-pay-32-5-million-to-settle-allegations-relating-to-cancer-screening-tests/hld01b25281a1a6834863b5690562a6de430f

18 page settlement

https://hr.cch.com/hld/SettlementagreementbetweenDOJOIGandGenomicHealthInc.pdf

###

###

The Department of Justice settlement with Genomic Health, Inc. is an unusually clear window into how Medicare billing rules, clinical workflows, and financial pressures can collide—and how that collision can be reinterpreted, in hindsight, as fraud. For a small hospital performing lung cancer surgeries, the case is not abstract. It maps directly onto a daily operational dilemma: how to obtain high-value genomic results for clinicians when the hospital cannot absorb a $4,000 test within a bundled payment, and yet cannot safely manipulate timing or billing without legal exposure.

At the center of the case is Medicare’s “14-day rule,” also known as the Date of Service (DOS) rule. Under this framework, molecular tests ordered within 14 days of a hospital discharge—whether inpatient or outpatient—are considered part of the hospital service. For inpatients, the cost is bundled into the Diagnosis-Related Group (DRG) payment. For outpatients, the hospital is financially responsible, even if it may later seek reimbursement. Only when the test is performed more than 14 days after discharge may the laboratory bill Medicare directly. This creates a stark discontinuity: a test performed on day 13 is the hospital’s financial burden; the same test on day 15 is billable by the lab to Medicare. The Genomic Health case is, in essence, about what happens when organizations attempt to navigate—or exploit—that discontinuity.

According to the settlement agreement and DOJ press materials, the government alleged that Genomic Health engaged in a coordinated, multi-year strategy to circumvent the 14-day rule, spanning roughly 2007 to 2020 (Settlement Agreement, Sept. 12, 2023, Recitals D; DOJ Press Release, Oct. 2, 2023). The allegations were not limited to isolated billing errors but described a systematic pattern of behavior. First, the company allegedly delayed or held test orders that had been placed within the 14-day window, so that the eventual date of service would fall outside the window and permit direct Medicare billing. The settlement explicitly states that Genomic Health “cancelled, delayed, held or otherwise did not process orders” in order to shift the billing outcome (Settlement Agreement, Recitals D(1)). Second, the company allegedly participated in or encouraged “cancel-and-reorder” behavior, whereby tests initially ordered within 14 days of discharge were cancelled and then reordered after the window elapsed. Importantly, DOJ emphasized not only active encouragement but also the “failure to discourage” such behavior (Settlement Agreement, Recitals D(2), D(4)).

Third, DOJ alleged that the company sometimes billed Medicare directly for tests that were clearly within the prohibited 14-day window, particularly in the outpatient setting, constituting straightforward violations of the rule (Settlement Agreement, Recitals D(3)). Fourth, the same cancel-and-reorder pattern was alleged in outpatient contexts as in inpatient ones, reinforcing the view of a systemic approach rather than isolated events. Finally, and perhaps most legally consequential, DOJ alleged that Genomic Health failed to bill hospitals for tests that should have been their financial responsibility, instead writing off those charges. This was characterized as remuneration to induce referrals, triggering the Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)) and, by extension, False Claims Act liability (Settlement Agreement, Recitals D(5)).

The financial resolution reflects the seriousness of these allegations: Genomic Health agreed to pay $32.5 million, with $16.25 million designated as restitution, and whistleblowers received approximately $5.7 million (DOJ Press Release, Oct. 2, 2023; Settlement Agreement, ¶¶1–2). While the settlement formally disclaims admission of liability, the factual narrative constructed by DOJ is unmistakable. The government repeatedly framed the conduct not merely as regulatory noncompliance but as behavior that “delayed tests for cancer patients for no reason other than to circumvent a Medicare requirement,” thereby prioritizing financial outcomes over patient care (DOJ Press Release, Oct. 2, 2023).

What transforms this case from a technical billing dispute into a fraud case are three interlocking elements: intent, pattern, and inducement. First, intent was inferred from the systematic nature of the conduct—repeated delays, consistent timing shifts, and coordinated interactions with providers. Second, the pattern extended over more than a decade, suggesting that the behavior was embedded in operational processes rather than arising from occasional ambiguity. Third, and critically, the alleged financial concessions—specifically the failure to collect payment from hospitals—introduced an Anti-Kickback dimension that independently supports liability. Even if the timing issues had been ambiguous, the provision of free or discounted services tied to referral patterns would raise substantial legal risk.

For a small hospital performing lung cancer surgeries, the implications are both immediate and sobering. The hospital faces a real economic constraint: genomic tests are expensive, often exceeding the marginal reimbursement embedded in DRG payments. Yet the Genomic Health case demonstrates that attempts to “solve” this problem through timing manipulation or informal financial arrangements can expose both the laboratory and the hospital to significant liability. Practices that may appear operationally reasonable—delaying a test by a few days, coordinating with a lab to reorder a test, or accepting a waived charge—can, when viewed collectively and retrospectively, be construed as a deliberate scheme to shift payment responsibility.

The safest and most defensible pathway for such a hospital is to align testing decisions with genuine clinical workflow rather than reimbursement considerations. One viable model is to structure genomic testing as part of post-discharge outpatient care, where the decision to order the test is made after discharge based on clinical evaluation, pathology results, or multidisciplinary tumor board discussion. In this scenario, the timing reflects real clinical decision-making rather than financial engineering, and the laboratory may legitimately bill Medicare if the test is performed outside the 14-day window. However, the distinction must be real and well-documented. If the decision to test is effectively made during the inpatient stay and merely deferred for billing reasons, the risk remains.

Equally important are internal controls and documentation. Hospitals must establish clear policies that separate clinical decision-making from financial considerations, prohibit cancel-and-reorder practices, and require documentation of the clinical rationale for the timing of tests. Patterns should be monitored: if nearly all tests cluster just beyond the 14-day threshold, this may invite scrutiny regardless of stated intent. Moreover, hospitals must avoid accepting financial concessions from laboratories that could be construed as remuneration. The Genomic Health case makes clear that even the failure to invoice can be interpreted as an inducement under the Anti-Kickback Statute.

Ultimately, the line between compliant behavior and fraud in this domain is not defined solely by the calendar. It is defined by whether timing reflects legitimate clinical care or is engineered to achieve a particular reimbursement outcome. The Genomic Health settlement illustrates that regulators will look beyond individual transactions to the broader pattern and purpose of conduct. For hospitals, especially smaller institutions operating under financial pressure, the lesson is not that genomic testing is infeasible, but that it must be integrated into care pathways in a manner that is both clinically authentic and rigorously documented. In this environment, compliance is not merely about following rules—it is about being able to demonstrate, convincingly and consistently, that patient care, rather than payment optimization, drives decision-making.